Home / Investments / Gilead Nears Deal to Buy Immunomedics for More Than $20 Billion

Gilead Nears Deal to Buy Immunomedics for More Than $20 Billion

The biotech drugmaker has a market value of roughly $10 billion, meaning that Gilead would be paying up for the company and its prized breast-cancer drug.

About Helen Hague

Avatar

Check Also

Oil Price Rally Signals Optimism on Global Growth

A recent rise in oil prices continued on Tuesday, sending crude to its highest level …

css.php
Font Resize